White Pine Capital LLC Purchases New Stake in AbbVie Inc. $ABBV

White Pine Capital LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV – Free Report) during the third quarter, Holdings Channel.com reports. The fund acquired 5,662 shares of the company’s stock, valued at approximately $1,481,000.

Several other large investors have also recently bought and sold shares of ABBV. Financial Freedom LLC purchased a new position in shares of AbbVie during the third quarter worth about $29,000. Burk Holdings LLC bought a new position in shares of AbbVie during the second quarter valued at about $30,000. Marquette Asset Management LLC lifted its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after acquiring an additional 48 shares during the last quarter. Principia Wealth Advisory LLC boosted its holdings in AbbVie by 38.9% during the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Finally, IMG Wealth Management Inc. grew its position in AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after acquiring an additional 153 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Key Headlines Impacting AbbVie

Investors following ABBV have been watching these headlines:

  • Positive Sentiment: AbbVie’s immunology sales grew 16.6% in the third quarter, led by Skyrizi and Rinvoq. Their momentum is helping lift sales expectations for 2026, although Humira continues to decline. How Did AbbVie’s Immunology Franchise Fare in Q3?
  • Positive Sentiment: AbbVie licensed Nxera Pharma’s EP4 agonist program for inflammatory bowel disease. The deal adds a potential pipeline asset, though its milestones depend on future development and other conditions. AbbVie Deal Altering the Investment Case for Nxera Pharma
  • Negative Sentiment: EVP Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. The sale could weigh on sentiment, though the filing did not state a reason. AbbVie EVP Sells $11,925,738.40 in Stock

AbbVie Stock Up 0.1%

Shares of AbbVie stock opened at $295.18 on Monday. The company has a market cap of $521.77 billion, a PE ratio of 50.81, a P/E/G ratio of 1.34 and a beta of 0.20. The business has a 50 day moving average of $275.51 and a 200 day moving average of $240.91. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. The business had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.86 earnings per share. On average, research analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a $1.82 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $275.00 price target on shares of AbbVie in a research note on Monday, November 2nd. Guggenheim increased their price objective on AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Piper Sandler raised their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Rothschild & Co Redburn lifted their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $297.46.

Check Out Our Latest Research Report on ABBV

Insider Activity at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president directly owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Read More

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.